➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Harvard Business School
Dow
Merck
Moodys

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Patent: 9,217,020

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,217,020
Title:Constructs for enhancement of gene expression in muscle
Abstract: Efficient and muscle-specific gene expression can be obtained with constructs containing two or more copies of USE and/or .DELTA.USE fused to the minimal promoter of the TnISlow gene. USE is a small (about 160-bp) upstream enhancer of the TnISlow gene that confers slow-twitch muscle fiber specificity. .DELTA.USE is generated from a 100-bp deletion at the 5\' end of USE. .DELTA.USE confers expression in slow- and fast-twitch muscle fibers. The strength and relatively small size (less than 600-bp) of these constructs make them useful for gene therapy applications.
Inventor(s): Blain; Marilyne (Lorraine, CA), Massie; Bernard (Laval, CA), Gilbert; Renald (Montreal, CA)
Assignee: National Research Council of Canada (Ottawa, CA)
Application Number:12/450,939
Patent Claims:see list of patent claims

Details for Patent 9,217,020

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial National Research Council of Canada (Ottawa, CA) 2027-04-17 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial National Research Council of Canada (Ottawa, CA) 2027-04-17 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial National Research Council of Canada (Ottawa, CA) 2027-04-17 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Baxter
Johnson and Johnson
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.